Table 5. Mesenchymal stem cell products with regulatory approval.

Mesenchymal stem cell product (company)	Approval granted (year)	Indication	Product type
Queencell (Anterogen Co. Ltd.)	South Korea (2010)	Subcutaneous tissue defects	Autologous human AT-MSC
Cellgram-AMI (Pharmicell Co. Ltd.)	South Korea (2011)	Acute myocardial infarction	Autologous human BM-MSC
Cartistem (Medipost Co. Ltd.)	South Korea (2012)	Knee articular cartilage defects	Allogeneic human UC-MSC
Cupistem (Anterogen Co. Ltd.)	South Korea (2012)	Crohn’s fistula	Autologous human BM-MSC
Prochymal, remestemcel-L (Osiris Therapeutics Inc., Mesoblast Ltd.)	Canada (2012) New Zealand (2012)	Graft versus host disease	Allogeneic human BM-MSC
Neuronata-R (Corestem Inc.)	South Korea (2014)	Amyotrophic lateral sclerosis	Autologous human BM-MSC
Temcell HS (JCR Pharmaceuticals)	Japan (2015)	Graft versus host disease	Allogeneic human BM-MSC
Stempeucel (Stempeutics Research PVT)	India (2016)	Critical limb ischemia	Allogeneic human BM-MSC
Alofisel (TiGenix NV/Takeda)	Europe (2018)	Complex perianal fistulas in Crohn’s disease	Allogeneic human AT-MSC
Stemirac (Nipro Corp)	Japan (2018)	Spinal cord injury	Autologous human BM-MSC

Note: Data are from Wright et al.,⁶² Pereira Chilima et al.⁶³ and Levy et al.⁶⁴ AT-MSC: adipose tissue mesenchymal stem cells; BMMSC: bone marrow mesenchymal stem cells.